Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708129 | 0.81 | MAPT (0.38) | MAPTCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5936811 | 0.77 | CHRM1 (0.35) | MAPTCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL27783691 | 0.75 | MAPT (0.35) | MAPTCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL15402934 | 0.74 | — | — | |
| SCHEMBL1707421 | 0.73 | LMNA (0.35) | MAPTCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL28221463 | 0.73 | CYP2D6 (0.34) | MAPTCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL29186047 | 0.71 | — | — | |
| SCHEMBL1708138 | 0.70 | — | — | |
| SCHEMBL25283329 | 0.70 | — | — | |
| SCHEMBL5936759 | 0.70 | CHRM1 (0.44) | MAPTCHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | claimed |
| CN-115954542-A | Lithium ion battery electrolyte and lithium ion battery | 九江天赐高新材料有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115668569-A | Electrolyte solution, electrochemical device, lithium ion secondary battery, and assembly | 大金工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-115668571-A | Electrolyte solution, electrochemical device, lithium ion secondary battery, module, and compound | 大金工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | disclosed |
| US-9283199-B2 | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms | CIMAS LIMITED (CY) | 2016-03-15 | — | — | US | disclosed |
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CIMAS LIMITED (CY) | 2016-03-10 | — | — | US | disclosed |
| US-20150244026-A1 | LITHIUM-ION SECONDARY BATTERY AND FORMULA FOR GEL ELECTROLYTE THEREOF | DONGGUAN AMPEREX TECHNOLOGY LIMITED (CN) | 2015-08-27 | — | — | US | disclosed |
| EP-2440198-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | Mardi Medicines Ltd. (IL) | 2012-04-18 | — | — | EP | disclosed |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2011-03-03 | — | — | US | disclosed |
| WO-2010143188-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | MAPT 3567/4885CHRM1 2072/4885AKR1A1 1744/4885 |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | MAPT 3567/4885CHRM1 2072/4885AKR1A1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.